2026 Mid-Year Update

The Directors of Inizio are pleased to present a mid-year update for 2026.

Inizio is the world’s largest integrated pharmaceutical commercialization partner, offering a complete suite of best-in-class and innovative scientific, medical, marketing, advisory, communications and patient engagement services through our 10,900 experts across 50 countries. We provide tailored, data-driven & technology-enabled solutions to life science companies that help them to navigate an increasingly complex commercialisation journey to optimise their product development, marketing and reach to maximise patient access.

In the past two years, we have partnered on more than 1,200 products across all major therapeutic areas with a significant proportion of these assets serving treatment needs of patients in the most innovative areas of medicine. We are a trusted partner of all the top 20 pharmaceutical companies, as well as for numerous leading mid-size pharma and biotech companies. Furthermore, we are a product launch powerhouse, helping our clients successfully plan and execute launch activity – in the past two years we have partnered with clients on approximately 85% of Top 20 launches of new innovative medicines in areas of significant patient need, many of which are projected to be market leaders in terms of commercial performance. Unlocking this value from our scaled platform for our clients and all patients is a strategic imperative, and we remain focussed on areas of greatest need, value and innovation.

The business delivered a good trading performance in the first half of 2026, underpinned by strong and improving market fundamentals, and the essential nature of the services we provide. Revenue momentum has continued to build year on year, reflecting increased activity with existing clients and increased spend per engagement, supported by sustained growth across the wider pharmaceutical and biotech sectors.

The Group’s trading remains in line with expectations and comfortably within the covenants of its debt facilities. We are well positioned to sustain strong performance through the second half of the year and to continue delivering on our growth strategy across the business.